U.S. Capital Wealth Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-335	Closed	-$53.4K	–	1092
2022 Q4	$53.4K	Buy	+335	New	+$49.1K	﹤0.01%	866

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

U.S. Capital Wealth Advisors's JAZZ Position: Q1 2023 in Review

U.S. Capital Wealth Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 335 shares — an estimated $53.4K sold.

U.S. Capital Wealth Advisors first reported a position in JAZZ in Q4 2022 and held it in 1 quarter. The position peaked at $53.4K in Q4 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

U.S. Capital Wealth Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
U.S. Capital Wealth Advisors sold 335 Jazz Pharmaceuticals shares in Q1 2023, an estimated $53.4K.
U.S. Capital Wealth Advisors first reported a position in Jazz Pharmaceuticals in Q4 2022 and held it in 1 quarter.
U.S. Capital Wealth Advisors's Jazz Pharmaceuticals position peaked at $53.4K in Q4 2022.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2023, filed 11 May 2023.